Stephen Smolinski
Corporate Officer/Principal bei PRECIGEN, INC.
Aktive Positionen von Stephen Smolinski
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
PRECIGEN, INC. | Corporate Officer/Principal | - | - |
Karriereverlauf von Stephen Smolinski
Ehemalige bekannte Positionen von Stephen Smolinski
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
CARTESIAN THERAPEUTICS, INC. | Corporate Officer/Principal | 01.10.2017 | 18.08.2020 |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Corporate Officer/Principal | 01.01.2015 | 01.01.2017 |
SAVIENT PHARMACEUTICALS INC | Vertrieb & Marketing | 02.05.2011 | 01.06.2013 |
SWEDISH ORPHAN BIOVITRUM AB | Corporate Officer/Principal | - | - |
AVALO THERAPEUTICS, INC. | Corporate Officer/Principal | 03.01.2022 | - |
Ausbildung von Stephen Smolinski
Oregon State University | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 6 |
Vereinigtes Königreich | 2 |
Schweden | 2 |
Operativ
Corporate Officer/Principal | 5 |
Sales & Marketing | 1 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 7 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
AVALO THERAPEUTICS, INC. | Health Technology |
SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
PRECIGEN, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Savient Pharmaceuticals, Inc.
Savient Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Savient Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company, which develops, manufactures and markets pharmaceutical products. The company focuses on developing and commercializing KRYSTEXXA for the treatment of chronic gout in adult patients who do not respond to conventional therapy. It also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. The company was founded in 1980 is headquartered in East Brunswick, NJ. | Health Technology |
Selecta Biosciences, Inc.
Selecta Biosciences, Inc. BiotechnologyHealth Technology Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its portfolio includes pipeline, autoimmune, gene therapy, and biologic therapy. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian on December 10, 2007 and is headquartered in Watertown, MA. | Health Technology |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Health Technology |
- Börse
- Insiders
- Stephen Smolinski
- Erfahrung